Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial.

Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd.

Clin Ophthalmol. 2011;5:633-43. doi: 10.2147/OPTH.S19349. Epub 2011 May 15.

2.

A single-center study evaluating the effect of the controlled adverse environment (CAE(SM)) model on tear film stability.

Abelson R, Lane KJ, Rodriguez J, Johnston P, Angjeli E, Ousler G, Montgomery D.

Clin Ophthalmol. 2012;6:1865-72. doi: 10.2147/OPTH.S33905. Epub 2012 Nov 13.

3.

Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.

Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, Lama T, Cumberlidge G, Ousler GW 3rd.

Clin Ophthalmol. 2013;7:1275-85. doi: 10.2147/OPTH.S44688. Epub 2013 Jun 26.

4.
5.

Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis.

Cohen AE, Assang C, Patane MA, From S, Korenfeld M; Avion Study Investigators.

Ophthalmology. 2012 Jan;119(1):66-73. doi: 10.1016/j.ophtha.2011.07.006. Epub 2011 Nov 23.

PMID:
22115712
6.

Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.

Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N; Rebamipide Ophthalmic Suspension Phase II Study Group.

Ophthalmology. 2012 Dec;119(12):2471-8. doi: 10.1016/j.ophtha.2012.06.052. Epub 2012 Sep 23.

PMID:
23009892
7.

Evaluation of ocular and general safety following repeated dosing of dexamethasone phosphate delivered by transscleral iontophoresis in rabbits.

Patane MA, Schubert W, Sanford T, Gee R, Burgos M, Isom WP, Ruiz-Perez B.

J Ocul Pharmacol Ther. 2013 Oct;29(8):760-9. doi: 10.1089/jop.2012.0175. Epub 2013 Jul 11.

PMID:
23844757
8.

Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.

Mah FS, O'Brien T, Kim T, Torkildsen G.

Curr Med Res Opin. 2008 Feb;24(2):441-7. doi: 10.1185/030079908X261078 .

PMID:
18167176
10.

SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.

Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G.

Adv Ther. 2016 Jan;33(1):96-115. doi: 10.1007/s12325-015-0274-5. Epub 2016 Jan 5.

12.

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ.

Cornea. 2004 Nov;23(8):784-92. Erratum in: Cornea. 2007 May;26(4):514.

PMID:
15502479
14.

Clinical performance of a mid-viscosity artificial tear for dry eye treatment.

Simmons PA, Vehige JG.

Cornea. 2007 Apr;26(3):294-302.

PMID:
17413956
16.

Acupuncture for treating dry eye: a randomized placebo-controlled trial.

Shin MS, Kim JI, Lee MS, Kim KH, Choi JY, Kang KW, Jung SY, Kim AR, Kim TH.

Acta Ophthalmol. 2010 Dec;88(8):e328-33. doi: 10.1111/j.1755-3768.2010.02027.x. Epub 2010 Nov 10.

18.

Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.

Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K; Diquafosol Ophthalmic Solution Phase 2 Study Group.

Ophthalmology. 2012 Oct;119(10):1954-60. doi: 10.1016/j.ophtha.2012.04.010. Epub 2012 Jun 26.

PMID:
22739038
19.
20.

Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy.

Gomes PJ, Ousler GW, Welch DL, Smith LM, Coderre J, Abelson MB.

Clin Ophthalmol. 2013;7:157-65. doi: 10.2147/OPTH.S38732. Epub 2013 Jan 20.

Items per page

Supplemental Content

Write to the Help Desk